Evidence map›Paper›PMID 40830401›Full record

ArticleScientific reports2025

Corneal changes in estrogen-dependent breast cancer after hormonal treatment.

Mohamed Salah Hamed Mohamed, Alaa Mahmoud, Haitham Thabit Abd Alkareem Rashdan, Elshimaa A Mateen Mousa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Mohamed Salah Hamed MohamedDepartment of Ophthalmology, Faculty of Medicine, Sohag University, Sohag, Egypt. Mohsalah513@gmail.com.
Alaa MahmoudDepartment of Ophthalmology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Haitham Thabit Abd Alkareem RashdanDepartment of Ophthalmology, Faculty of Medicine, Sohag University, Sohag, Egypt.
Elshimaa A Mateen MousaDepartment of Ophthalmology, Faculty of Medicine, Sohag University, Sohag, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aromatase inhibitors (AI) therapy is the treatment of choice for estrogen receptor-positive breast cancer (BC). While AIs effectively suppress tumor growth, estrogen deprivation may have negative impacts on the eyes. This work evaluated the anterior segment changes in estrogen-dependent BC after hormonal treatment. This cross-sectional study was conducted on 40 female patients aged ≥ 18 who received treatment for BC. Patients were allocated to two groups: Group A served as the control group and did not receive AIs, while Group B received one of the AIs for BC treatment. Before treatment, there was no significant difference in tear break-up time (TBUT), Schirmer test (ST) score, and hexagonality. However, post-treatment TBUT and ST values were lower in Patients who received treatment. Corneal thickness, CCT, or back and front elevations were comparable before or after treatment. AI therapy in estrogen-dependent BC patients is associated with significant corneal changes, including potential corneal stress evidenced by impaired tear film function and reduced endothelial hexagonality, while corneal thickness and front and back elevation remain stable.

Indexed as

Aromatase InhibitorsBreast NeoplasmsCorneaEstrogensAdultAgedCross-Sectional StudiesFemaleHumansMiddle AgedAromatase InhibitorsEstrogensAromatase inhibitorsBreast cancerCorneal changesEstrogenHormonal treatment

Identifiers

PMID40830401
PMCPMC12365155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.